Clinical trial · Observational
Molecular Genetic, Host-derived and Clinical Determinants of Long-term Survival in Glioblastoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This pro - and retrospective multicenter clinical epidemiological study studies the molecular genetic, host-derived and clinical determinants of glioblastoma patients with an overall survival of more than 5 years. The different research focusses are: * Identification of clinical parameters and patient characteristics / host-related factors in long-term survivors (Focus 1) * Identification of molecular tumor characteristics in long-term survivors (Focus 2) * Assessment of therapy-related parameters, including neuro-toxicity (Focus 3) * Immunological studies (Focus 4)
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Glioblastoma | Glioblastoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood drawl | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (7)
- measure
- Overall Survival
- timeFrame
- 1 year from last patient in
- measure
- Molecular profiling on FFPE samples
- timeFrame
- 1 year from last patient in
- description
- Profiling for cytosine-phosphate-guanosine (CpG) methylation patterns using the Illumina 850k bead array platform
- measure
- Molecular profiling on frozen samples
- timeFrame
- 1 year from last patient in
- description
- Samples will be subjected to whole exome sequencing
- measure
- Molecular profiling on frozen samples
- timeFrame
- 1 year from last patient in
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age \> 18 years at diagnosis * Histopathological diagnosis of glioblastoma (reference histology available) and * Survival \>5 years from diagnosis * Availability of tumor tissue from initial glioblastoma diagnosis (FFPE or fresh-frozen) to validate the diagnosis centrally. * Signed consent form (living patients) or ethics approval for anonymous data collection in case of retrospective analysis of deceased patients Exclusion Criteria: * Not applicable
References
Publications (0)
Data not yet available